Results 81 to 90 of about 8,229 (214)

Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4 [PDF]

open access: yes
Ovarian cancer (OC) is the most lethal gynaecologic malignancy, attributed to its insidious growth, non-specific symptoms and late presentation. Unfortunately, current screening modalities are inadequate at detecting OC and many lack the appropriate ...
Makker, S.   +12 more
core   +1 more source

Prognostic values of HE4 expression in patients with cancer: a meta-analysis

open access: yes, 2018
Cong Dai,1,2,* Yi Zheng,2,* Yuanjie Li,3 Tian Tian,2 Meng Wang,2 Peng Xu,2 Yujiao Deng,2 Qian Hao,2 Ying Wu,2 Zhen Zhai,2 Zhijun Dai,2 Jun Lyu1 1Clinical Research Center, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an ...
Wang M   +11 more
core  

Correlation of Human Epididymis Protein 4 Expression with Clinicopathologic Parameters in Gastric Carcinomas

open access: yesHamidiye Medical Journal
Background: Human epididymis protein 4 (HE4) was discovered in 1991 as a glycoprotein secreted from the cells of the human epididymal epithelium and associated with sperm development and immunity.
Pınar Öksüz   +4 more
doaj   +1 more source

Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer

open access: yesFrontiers in Oncology, 2018
Human epididymis protein 4 (HE4) is an important clinical biomarker used for the detection of epithelial ovarian cancer (EOC). While much is known about the predictive power of HE4 clinically, less has been reported regarding its molecular role in the ...
Nicole E. James   +3 more
doaj   +1 more source

Epitel Over Kanserleri ve Benign Adneksiyal Kitlelerde Human Epididymis Protein 4 ile Hesaplanan Malignite Risk İndeksi

open access: yesGenel Tıp Dergisi, 2019
Amaç: Over kanseri kadınlarda kanser türleri arasında 7. sırada yer almaktadır ancak jinekolojik kanserler arasında en yüksek mortaliteye sahiptir.
Canan Topçuoğlu   +2 more
doaj  

HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial

open access: yesFrontiers in Oncology
HE4 and CA-125 are used for epithelial ovarian cancer (EOC) screening, diagnosis, and follow-up. Our objective was to study HE4 and CA-125 kinetics in patients treated for recurrent EOC.
Michel Fabbro   +6 more
doaj   +1 more source

Serum CA125 and HE4 levels combined with magnetic resonance imaging (MRI) in the clinical diagnostic value of ovarian neoplasms

open access: yesJournal of Radiation Research and Applied Sciences
Objective: The study aimed to assess the clinical significance of serum markers Cancer Antigen 125(CA125) and Human Epididymis Protein 4(HE4) combined with MRI in distinguishing between benign and malignant ovarian tumors. Methods: Analyzing 140 patients
Xun Mao, Wei Chen
doaj   +1 more source

外周血循环细胞和三种肿瘤标志物检测对Ⅰ期子宫内膜癌的诊断价值

open access: yesZhongshan Daxue xuebao. Yixue kexue ban, 2022
目的探讨外周血循环肿瘤细胞(CTC)和三种肿瘤标志物检测对Ⅰ期子宫内膜癌(EC)的诊断价值,为寻找一种无创的早期EC诊断方法提供科学依据。方法选取2016年5月至2021年11月期间,335例健康女性体检者(对照组)、291例子宫内膜良性病变患者(良性病变组)、268例Ⅰ期EC患者(EC组)为研究对象,抽取体检者,患者的术前静脉血液标本3.2 mL,采用免疫荧光杂交和染色技术测定CTC水平,乳胶增强免疫比浊法测定SAA水平,电化学发光法测定HE4、CA125水平,观察3组研究对象的CTC、SAA、HE4、
蔡春芳, 古家美, 官燕飞
doaj  

Human epididymis protein 4 is a useful predictor of post‐operative prognosis in patients with severe aortic stenosis

open access: yesESC Heart Failure
Aims The human epididymis protein 4 (HE4), a novel fibrosis marker, is expressed only in activated fibroblasts and is thought to reflect ongoing left ventricular (LV) fibrosis. LV fibrosis is a feature of severe aortic stenosis (AS) and is related to the
Fumihiko Ogata   +20 more
doaj   +1 more source

Analysis of serum level of HE4 and CA125 considering selected risk factors among patients with endometrioid endometrial cancer

open access: yes, 2017
The aim of the study : To assess the difference of serum level of HE4 and CA125 among patients with endometrioid endometrial cancer, considering the presence or absence of selected risk factors.
Malgorzata Kania   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy